Factors associated with patency of self-expandable metal stents in malignant biliary obstruction
Issued Date
2023-12-01
Resource Type
eISSN
1471230X
Scopus ID
2-s2.0-85176356823
Journal Title
BMC Gastroenterology
Volume
23
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Gastroenterology Vol.23 No.1 (2023)
Suggested Citation
Suksai N., Kamalaporn P., Chirnaksorn S., Siriyotha S. Factors associated with patency of self-expandable metal stents in malignant biliary obstruction. BMC Gastroenterology Vol.23 No.1 (2023). doi:10.1186/s12876-023-03028-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/91109
Title
Factors associated with patency of self-expandable metal stents in malignant biliary obstruction
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Introduction: Endoscopic self-expandable metal stent (SEMS) placement is the key endoscopic treatment for unresectable malignant biliary obstruction. The benefit of covered SEMS over uncovered SEMS remains unknown as are risk factors for SEMS dysfunction. This study aimed to determine the factors associated with patency of SEMS. Methods: Patients with unresectable malignant biliary obstruction who underwent endoscopic SEMS placement at Ramathibodi Hospital, during January 2012 to March 2021 were included. Patient characteristics, clinical outcomes and patency of SEMS were collected. The primary outcome were stent patency and factors associated with patency of SEMS. The factors were analyzed by univariate and multivariate analyses. Median days of stent patency, median time of patient survival, rate of reintervention and complications after SEMS placement were collected. Results: One hundred and fourteen patients were included. SEMS dysfunction was found in 37 patients (32.5%). Size of cancer (Hazard ratio (HR), 1.20, (95% CI 1.02, 1.40), p 0.025), presence of stones or sludge during SEMS placement (Hazard ratio (HR), 3.91, (95% CI 1.74, 8.75), p 0.001), length of SEMS, 8 cm (HR 2.96, (95% CI 1.06, 8.3), p 0.039), and total bilirubin level above 2 mg/dL at one month after SEMS placement (HR 1.14, (95% CI 1.06, 1.22), p < 0.001) were associated with SEMS dysfunction. The median stent patency was 97 days. The median patient survival was 133 days, (95% CI 75–165). The rate of reintervention was 86% in patients with SEMS dysfunction. Conclusion: The size of cancer, presence of stones or sludge during SEMS placement, the length of SEMS, and total bilirubin level above 2 mg/dL at 1 month after SEMS placement were associated with SEMS dysfunction. The median time of stent patency were not statistically different in each type of stent, covered stent, partially covered stent and uncovered stent. Median survival time of patients did not associate with SEMS patency or dysfunction.